#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16740	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2532	817.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1950	1950	T	1067	T,C	1066,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16740	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2532	817.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1684	1684	C	1072	C,T,G	1070,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28544	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3974	896.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1901	1901	A	1140	A	1140	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28544	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3974	896.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2535	2535	C	1036	C	1036	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28544	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3974	896.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2609	2609	A	1012	A,C,G	1010,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28544	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3974	896.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3161	3161	C	995	C,T,G,A	988,3,2,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2354	folP	855	855	100.0	folP.l15.c4.ctg.1	2035	144.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1174	1176	AGC	248;250;252	A;G,T;C	248;249,1;252	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5368	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3812	175.9	1	SNP	p	S91F	1	.	.	271	273	TTC	803	805	TTC	217;218;220	T;T,A;C,A	217;217,1;219,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5368	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3812	175.9	1	SNP	p	D95G	1	.	.	283	285	GGC	815	817	GGC	220;223;222	G;G;C,A	220;223;221,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5368	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3812	175.9	1	SNP	p	G95N	0	.	.	283	285	GGC	815	817	GGC	220;223;222	G;G;C,A	220;223;221,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	2072	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1751	147.7	1	SNP	p	G45D	0	.	.	133	135	GGC	631	633	GGC	237;237;237	G;G,T;C	237;236,1;237	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1124	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1357	103.1	0	.	n	.	0	A197.	DEL	197	197	A	732	732	A	226	A	226	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5176	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3479	185.7	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1880	1882	GCA	266;267;275	G,A;C;A	265,1;267;275	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5176	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3479	185.7	1	SNP	p	D86N	0	.	.	256	258	GAC	833	835	GAC	243;241;243	G;A;C	243;241;243	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5176	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3479	185.7	1	SNP	p	R87W	0	.	.	259	261	CGT	836	838	CGT	243;243;241	C,A;G;T,G,C	242,1;243;239,1,1	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5176	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3479	185.7	1	SNP	p	R87I	0	.	.	259	261	CGT	836	838	CGT	243;243;241	C,A;G;T,G,C	242,1;243;239,1,1	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5176	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3479	185.7	1	SNP	p	S87R	1	.	.	259	261	CGT	836	838	CGT	243;243;241	C,A;G;T,G,C	242,1;243;239,1,1	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5176	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3479	185.7	1	SNP	p	S88P	0	.	.	262	264	TCC	839	841	TCC	242;242;241	T;C;C,G	242;242;240,1	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4742	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3071	192.8	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1580	1582	TGC	236;234;237	T;G;C,T	236;234;236,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4742	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3071	192.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1790	1792	GGC	273;271;267	G;G;C	273;271;267	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	4432	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2929	188.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1530	1532	GCA	309;310;307	G;C;A	309;310;307	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4432	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2929	188.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1533	1535	ATC	310;311;308	A;T,A;C,G	310;310,1;307,1	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4432	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2929	188.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1545	1547	GTG	308;308;308	G;T;G	308;308;308	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4432	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2929	188.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1545	1547	GTG	308;308;308	G;T;G	308;308;308	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4432	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2929	188.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2049	2051	ACC	253;249;247	A;C;C,T	253;249;246,1	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4432	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2929	188.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2103	2105	GCG	240;238;237	G;C,G;G	240;237,1;237	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4432	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2929	188.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2103	2105	GCG	240;238;237	G;C,G;G	240;237,1;237	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4432	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2929	188.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2226	2228	GGC	260;261;262	G,A;G;C	259,1;261;262	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4432	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2929	188.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2235	2237	GGC	264;262;263	G;G;C	264;262;263	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4432	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2929	188.9	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2253	2255	TCG	256;259;254	T,G;C;G	255,1;259;254	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5998	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3568	210.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1839	1841	CCG	254;252;252	C;C;G,A	254;252;251,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2508	porA	1146	1146	99.56	porA.l15.c4.ctg.1	2164	144.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	720	720	C	210	C	210	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	330	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	306	37.6	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	31;33;35	T;T;A	31;33;35	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	330	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	306	37.6	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	74;74;74	C;A;T	74;74;74	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	330	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	306	37.6	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	74;74;74	A;G;T	74;74;74	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	330	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	306	37.6	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	74;74;74	T;A;C	74;74;74	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	330	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	306	37.6	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	4;5;5	G;C;A	4;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	330	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	306	37.6	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	5;5;5	G;C;A	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	330	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	306	37.6	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	5;5;5	G;A;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	330	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	306	37.6	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	6;6;6	A;T;C	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	330	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	306	37.6	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	6;6;6	T;C;G	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	330	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	306	37.6	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	7;7;7	G;C;C	7;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	330	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	306	37.6	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	7;8;8	A;G;C	7;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	330	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	306	37.6	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	8;8;8	G;C;C	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	330	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	306	37.6	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	8;8;8	G;T;T	8;8;8	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3400	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1864	226.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	599	601	GAA	348;352;353	G;A;A	348;352;353	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3400	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1864	226.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	887	889	GAT	304;304;300	G,A;A;T	303,1;304;300	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3400	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1864	226.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1010	1012	TCA	327;326;322	T;C;A,C	327;326;321,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3400	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1864	226.9	0	.	p	.	0	F215T	NONSYN	643	645	TTT	1130	1132	ACT	310;308;308	A;C;T,G	310;308;306,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3400	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1864	226.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1139	1141	GTG	312;312;309	G;T;G,C	312;312;308,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3400	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1864	226.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1469	1471	GCA	271;272;273	G,T;C,A;A	270,1;271,1;273	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3400	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1864	226.9	1	SNP	p	G120K	1	.	.	358	360	AAG	845	847	AAG	305;308;309	A;A;G,T	305;308;308,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3400	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1864	226.9	1	SNP	p	A121D	1	.	.	361	363	GAC	848	850	GAC	308;306;309	G;A;C	308;305;308	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3400	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1864	226.9	1	SNP	p	D121N	0	.	.	361	363	GAC	848	850	GAC	308;306;309	G;A;C	308;305;308	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11504	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	5333	269.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2228	2230	AAT	301;300;300	A;A;T	301;300;300	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1602	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1358	147.0	1	SNP	p	V57M	1	.	.	169	171	ATG	720	722	ATG	273;273;273	A;T,G;G	273;272,1;273	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
